CClinicalTrials.gg
Not yet recruitingNCT07847099Updated Sep 29, 2026

Platelet Indices and Blood Groups in Type 2 Diabetes Vascular Complications

An observational study in Type 2 Diabetes Mellitus and Vascular Complications, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

This cross-sectional study aims to evaluate the association of platelet indices and ABO blood groups with vascular complications in patients with type 2 diabetes mellitus.

Read the detailed description

Vascular complications are a major cause of morbidity in type 2 diabetes mellitus. Platelet indices and ABO blood groups may be related to these complications.

This observational study will include adult patients with type 2 diabetes mellitus. Patients will be classified into those with and without vascular complications. Platelet indices (MPV, PDW) and ABO blood groups will be assessed.

02

Conditions studied

  • Type 2 Diabetes Mellitus
  • Vascular Complications

Keywords

  • Platelet indices
  • MPV
  • Type 2 diabetes
  • ABO blood group
  • Assiut
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with type 2 diabetes mellitus attending the Internal Medicine Department and Diabetes Center at Assiut University Hospital.

Inclusion criteria

  • Age 18 years or older
  • Confirmed diagnosis of type 2 diabetes mellitus according to ADA criteria
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Gestational diabetes
  • Acute infection or sepsis
  • Hematological disorders affecting platelet count or function
  • Malignancy
  • Chronic liver disease
  • Autoimmune diseases
  • Current anticoagulant or antiplatelet therapy
  • Recent major surgery or trauma
  • Pregnancy
04

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • T2DM with Vascular Complications

    Patients with type 2 diabetes mellitus who have microvascular or macrovascular complications.

  • T2DM without Vascular Complications

    Patients with type 2 diabetes mellitus who have no microvascular or macrovascular complications.

05

What researchers measure

Primary outcomes

  1. Mean platelet volume in patients with and without vascular complications

    Mean platelet volume (MPV) in femtoliters compared between type 2 diabetes patients with vascular complications and those without vascular complications.

    Time frame: Baseline

Secondary outcomes

  1. Mean platelet distribution width

    Mean platelet distribution width (PDW) compared between patients with and without vascular complications.

    Time frame: Baseline

  2. Distribution of ABO blood groups according to vascular complications

    Frequency and percentage of ABO blood groups in patients with and without vascular complications.

    Time frame: Baseline

  3. Mean platelet volume according to ABO blood group

    Mean platelet volume (MPV) among different ABO blood groups.

    Time frame: Baseline

  4. Prevalence of microvascular complications

    Proportion of patients with microvascular complications (retinopathy, nephropathy, or neuropathy).

    Time frame: Baseline

  5. Prevalence of macrovascular complications

    Proportion of patients with macrovascular complications (coronary artery disease, cerebrovascular disease, or peripheral arterial disease).

    Time frame: Baseline

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07847099
Lead sponsor
Assiut University
Responsible party
Nehal Sayed Mohammed Sayed (Resident Physician, Department of Internal Medicine, Assiut University) — Principal investigator
First posted
Sep 29, 2026
Start date
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Completion
Mar 25, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Nehla S Mohamed, Resident
Contact
Nehal.18313533@med.aun.edu.eg
01023327969
Lobna F El-toony
study chair · Internal Medicine Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion